Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING
BioConferenceLive
JIB

Switch to CAD Technology Greatly Improves Lab-On-A-Chip Capability

By BiotechDaily International staff writers
Posted on 12 May 2014
The lab-on-a-chip holds potential for reducing cost of medical diagnostics while expanding access to health care. Now scientists have developed computer aided design (CAD) software to enable far more than one or two tests on a single chip.

In the near future healthcare professionals may be able to routinely run clinical lab tests almost instantly on a digital microfluidic machine about the size of credit card. These lab-on-a-chips (LOCs) would not only be quick—results available in minutes—but also inexpensive and portable. They could be used at point-of-care, and even at long distance from the nearest medical clinic.

But as powerful as they may be, they could be far better, said Shiyan Hu, associate professor of electrical and computer engineering at Michigan Technological University (MTU; Houghton, MI, USA). Current LOCs can generally run no more than a test or two because the chips are designed manually. If the LOCs were made using computer-aided design (CAD), you could run dozens of tests with, for example, a single drop of blood. “In a very short time, you could test for many conditions,” said Prof. Hu; “This really would be an entire lab on a chip.” With PhD student Chen Liao, Prof. Hu has taken the first step. “We have developed software to design the hardware,” he said.

Their work, described in, and featured on the cover of, the March, 2014, edition of the journal IEEE Transactions on Nanobiosciences, focuses on routing a droplet of blood or other fluid through each test on the chip efficiently while avoiding contamination. A key part in LOC CAD is physical-level synthesis. It includes the LOC placement and routing, where placement is to determine the physical location and the starting time of each operation, and routing is to transport each droplet from the source to the destination.

“It has taken us four years to do the software, but to manufacture the LOC would be inexpensive,” said Prof. Hu; “The materials are very cheap, and the results are more accurate than a conventional lab’s.” Prof. Hu plans to fabricate their own biochip using their software.

Related Links:

Michigan Technological University



comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: In the liver tissue of obese animals with type II diabetes, unhealthy, fat-filled cells are prolific (small white cells, panel A). After chronic treatment through FGF1 injections, the liver cells successfully lose fat and absorb sugar from the bloodstream (small purple cells, panel B) and more closely resemble cells of normal, non-diabetic animals (Photo courtesy of the Salk Institute for Biological Studies).

Fibroblast Growth Factor 1 Treatment Restores Glucose Control in Mouse Diabetes Model

A "vaccine" based on the metabolic regulator fibroblast growth factor 1 (FGF1) removed the insulin resistance that characterizes type II diabetes and restored the body's natural ability to manage its glucose... Read more

Drug Discovery

view channel
Image: Molecular rendering of the crystal structure of parkin (Photo courtesy of Wikimedia Commons).

Cinnamon Feeding Blocks Development of Parkinson's Disease in Mouse Model

A team of neurological researchers has identified a molecular mechanism by which cinnamon acts to protect neurons from damage caused by Parkinson's disease (PD) in a mouse model of the syndrome.... Read more

Therapeutics

view channel
Image: This type of electronic pacemaker could become obsolete if induction of biological pacemaker cells by gene therapy proves successful (Photo courtesy of Wikimedia Commons).

Gene Therapy Induces Functional Pacemaker Cells in Pig Heart Failure Model

Cardiovascular disease researchers working with a porcine heart failure model have demonstrated the practicality of using gene therapy to replace implanted electronic pacemakers to regulate heartbeat.... Read more

Business

view channel

Cancer Immunotherapy Sector Predicted to Surge to USD 9 Billion Across Major Pharma Through 2022

The immunotherapy market will experience substantial growth through 2022, increasing from USD 1.1 billion in 2012 to nearly USD 9 billion in 2022 (corresponding to 23.8% annual growth) in the United Kingdom, United States, France, Germany, Italy, Spain, and Japan, according to recent market research. This notable growth... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.